The challenges of prevention, diagnosis and treatment of ischemic heart disease in women

Cardiovascular Drugs and Therapy

Volumn 29, Issue 4, 2015, Pages 355-368

  Brewer, LaPrincess C ^a   Svatikova, Anna ^a   Mulvagh, Sharon L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiovascular risk; Diagnosis; Ischemic heart disease; Treatment; Women

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ALDOSTERONE ANTAGONIST; AMINOPHYLLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP PHOSPHODIESTERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PRAVASTATIN; RANOLAZINE; REGADENOSON; ROSUVASTATIN; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; CORONARY FLOW RESERVE; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOPPLER FLOWMETRY; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; EXERCISE TEST; FEMALE; FRAMINGHAM RISK SCORE; HEALTH CARE COST; HEALTH STATUS; HEART FAILURE; HEART INFARCTION; HEART REHABILITATION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INTRACORONARY DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MENOPAUSE; METABOLIC SYNDROME X; MICROVASCULATURE; MORBIDITY; MORTALITY; NON INVASIVE PROCEDURE; OBESITY; OSTEOPOROSIS; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; SYMPTOM; UNSTABLE ANGINA PECTORIS; WOMEN'S HEALTH; MYOCARDIAL ISCHEMIA; RISK FACTOR;

FEMALE; HUMANS; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; RISK FACTORS;

EID: 84943365428     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6607-4     Document Type: Article

References (140)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation. 2015;131:e29-e322
2. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the nhlbi-sponsored women’s ischemia syndrome evaluation (wise) study: Part i: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47:S4-S20
3. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54:1561-75
4. Kim ES, Carrigan TP, Menon V. Enrollment of women in national heart, lung, and blood institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. J Am Coll Cardiol. 2008;52:672-3
5. Bucholz EM, Butala NM, Rathore SS, Dreyer RP, Lansky AJ, Krumholz HM. Sex differences in long-term mortality after myocardial infarction: a systematic review. Circulation. 2014;130: 757-67
6. Wenger NK. Women and coronary heart disease: a century after Herrick: understudied, underdiagnosed, and undertreated. Circulation. 2012;126:604-11
7. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009;169:1762-6
8. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325:756-62
9. Campisi R. Noninvasive assessment of coronary microvascular function in women at risk for ischaemic heart disease. Int J Clin Pract. 2008;62:300-7
10. Mack M, Gopal A. Epidemiology, traditional and novel risk factors in coronary artery disease. Cardiol Clin. 2014;32:323-32
11. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the american heart association. Circulation. 2010;121:948
12. Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd- Jones DM. Racial differences in risks for first cardiovascular events and noncardiovascular death: the atherosclerosis risk in communities study, the cardiovascular health study, and the multi-ethnic study of atherosclerosis. Circulation. 2012;126:50-9
13. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the us from 1980 through 2002: Concealed leveling of mortality rates. J Am Coll Cardiol. 2007;50:2128-32
14. Dreyer RP, Smolderen KG, Strait KM, Beltrame JF, Lichtman JH, Lorenze NP, et al. Gender differences in pre-event health status of young patients with acute myocardial infarction: a virgo study analysis. Eur Heart J Acute Cardiovasc Care. in press
15. Zuchi C, Tritto I, Ambrosio G. Angina pectoris in women: focus on microvascular disease. Int J Cardiol. 2013;163:132-40
16. Hemingway H, Langenberg C, Damant J, Frost C, Pyörälä K, Barrett-Connor E. Prevalence of angina in women versus men a systematic review and meta-analysis of international variations across 31 countries. Circulation. 2008;117:1526-36
17. Mieres JH, Heller GV, Hendel RC, Gulati M, Boden WE, Katten D, et al. Signs and symptoms of suspected myocardial ischemia in women: results from the what is the optimal method for ischemia evaluation in women? Trial J Womens Health. 2011;20:1261-8
18. Eastwood J-A, Johnson BD, Rutledge T, Bittner V, Whittaker KS, Krantz DS, et al. Anginal symptoms, coronary artery disease, and adverse outcomes in black and white women: the nhlbi-sponsored women’s ischemia syndrome evaluation (wise) study. J Womens Health. 2013;22:724-32
19. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the women’s ischemia syndrome evaluation study and the st james women take heart project. Arch Intern Med. 2009;169:843-50
20. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, et al. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the bari 2d trial (bypass angioplasty revascularization investigation 2 diabetes). J Am Coll Cardiol. 2013;61:1767-76
21. Vaccarino V. Ischemic heart disease in women many questions, few facts. Circ Cardiovasc Qual Outcomes. 2010;3:111-5
22. Sharaf BL, Pepine CJ, Kerensky RA, Reis SE, Reichek N, Rogers WJ, et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the nhlbisponsored women’s ischemia syndrome evaluation [wise] study angiographic core laboratory). Am J Cardiol. 2001;87:937-41
23. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, et al. The economic burden of angina in women with suspected ischemic heart disease: results from the national institutes of health- national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation. Circulation. 2006;114:894-904
24. Shaw LJ, Shaw RE, Merz CNB, Brindis RG, Klein LW, Nallamothu B, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and inhospital mortality in the american college of cardiology-national cardiovascular data registry. Circulation. 2008;117:1787-801
25. Maynard C, Fisher L, Passamani E, Pullum T. Blacks in the coronary artery surgery study: risk factors and coronary artery disease. Circulation. 1986;74:64-71
26. Gulati M, Shaw LJ, Merz B, Noel C. Myocardial ischemia in women: lessons from the nhlbi wise study. Clin Cardiol. 2012;35:141-8
27. Bransford TL, Ofili E. The paradox of coronary heart disease in african-american women. J Natl Med Assoc. 2000;92:327
28. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the united states. Health Aff. 2007;26:38-48
29. Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA. Fifteen-year trends in awareness of heart disease in women results of a 2012 american heart association national survey. Circulation. 2013;127:1254-63
30. Papakonstantinou NA, Stamou MI, Baikoussis NG, Goudevenos J, Apostolakis E. Sex differentiation with regard to coronary artery disease. J Cardiol. 2013;62:4-11
31. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol. 2014;64:337-45
32. van Loo HM, van den Heuvel ER, Schoevers RA, Anselmino M, Carney RM, Denollet J, et al. Sex dependent risk factors for mortality after myocardial infarction: Individual patient data metaanalysis. BMC Med. 2014;12:242
33. Vaccarino V, Horwitz RI, Meehan TP, Petrillo MK, Radford MJ, Krumholz HM. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction. Arch Intern Med. 1998;158:2054-62
34. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. N Engl J Med. 1999;341:217-25
35. Berger JS, Brown DL. Gender-age interaction in early mortality following primary angioplasty for acute myocardial infarction. Am J Cardiol. 2006;98:1140-3
36. Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the nih-nhlbi-sponsored women’s ischaemia syndrome evaluation (wise) study. Eur Heart J. 2006;27:1408-15
37. Banks K, Lo M, Khera A. Angina in women without obstructive coronary artery disease. Curr Cardiol Rev. 2010;6:71
38. Handberg EM, Eastwood JA, Eteiba W, Johnson BD, Krantz DS, Thompson DV, et al. Clinical implications of the women’s ischemia syndrome evaluation: Inter-relationships between symptoms, psychosocial factors and cardiovascular outcomes. Womens Health (Lond Engl). 2013;9:479-90
39. Norris CM, Spertus JA, Jensen L, Johnson J, Hegadoren KM, Ghali WA. Sex and gender discrepancies in health-related quality of life outcomes among patients with established coronary artery disease. Circ Cardiovasc Qual Outcomes. 2008;1:123-30
40. Vaccarino V, Lin ZQ, Kasl SV, Mattera JA, Roumanis SA, Abramson JL, et al. Gender differences in recovery after coronary artery bypass surgery. J Am Coll Cardiol. 2003;41:307-14
41. Scheuner MT, Setodji CM, Pankow JS, Blumenthal RS, Keeler E. Relation of familial patterns of coronary heart disease, stroke, and diabetes to subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. Genet Med. 2008;10:879-87
42. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J. 1987;114:413-9
43. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-9
44. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54: 2366-73
45. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-90
46. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9
47. Reuterwall C, Hallqvist J, Ahlbom A, De Faire U, Diderichsen F, Hogstedt C, et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the sheep study. The sheep study group. J Intern Med. 1999;246:161-74
48. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297-305
49. Steliga MA, Dresler CM. Smoking cessation: crucial to target women as well as men. Lancet. 2011;378:1278-9
50. Sharma K, Gulati M. Coronary artery disease in women: a 2013 update. Glob Health. 2013;8:105-12
51. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl JMed. 2012;366: 321-9
52. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and associations with all-cause and cvd mortality among us adults. JAMA. 2012;307:1273-83
53. Kling JM, Miller VM, Mankad R, Wilansky S, Wu Q, Zais TG, et al. Go red for women cardiovascular health-screening evaluation: the dichotomy between awareness and perception of cardiovascular risk in the community. J Womens Health (Larchmt). 2013;22:210-8
54. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the women’s ischemia syndrome evaluation (wise) study. Circulation. 2004;109:706-13
55. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-hdl cholesterol, apolipoproteins a-i and b100, standard lipid measures, lipid ratios, and crp as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-33
56. Wong ND, Pio J, Valencia R, Thakal G. Distribution of c-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the national health and nutrition examination survey (nhanes) iii. Prev Cardiol. 2001;4:109-14
57. Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA, Hwang J, et al. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause. 2010;17: 785-90
58. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121: 010
59. Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, Khaw KT, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab. 2009;94: 4953-60
60. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the nhlbi-sponsored wise study. J Am Coll Cardiol. 2003;41:413-9
61. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd- Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation. 2011;57:1404-23
62. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (champs): population-based retrospective cohort study. Lancet. 2005;366:1797-803
63. Han SH, Bae JH, Holmes Jr. DR, Lennon RJ, Eeckhout E, Barsness GW, et al. Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J. 2008;29:1359-69
64. Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the nhlbi wise study. Am Heart J. 2001;141:735-41
65. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol. 2011;36:291-318
66. Bairey Merz CN, Pepine CJ. Syndrome x and microvascular coronary dysfunction. Circulation. 2011;124:1477-80
67. von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf BL, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation (wise). Circulation. 2004;109:722-5
68. Houghton JL, Smith VE, Strogatz DS, Henches NL, Breisblatt WM, Carr AA. Effect of african-american race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension. 1997;29:706-14
69. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes Jr. DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-54
70. Madhok V, Fahey T. Cardiovascular risk estimation: important but may be inaccurate. BMJ. 2006;332(7555):1422
71. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011;5:325-80
72. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the score project. Eur Heart J. 2003;24:987-1003
73. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136
74. NCEP. Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation. 2002;106:3143
75. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297:611-9
76. Wenger NK. The Reynolds risk score: improved accuracy for cardiovascular risk prediction in women? Nat Clin Pract Cardiovasc Med. 2007;4:366-7
77. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 acc/aha guideline on the assessment of cardiovascular risk: a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;129:S49-73
78. Gulati M, Noel Bairey Merz C. New cholesterol guidelines and primary prevention in women. Trends Cardiovasc Med. 2014;25: 84-94
79. Ridker PM, Cook NR. Statins: New american guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762-5
80. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the women’s health study. JAMA Intern Med. 2014;174:1964-71
81. Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307:813-22
82. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GBJ, Feit F, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124:1414-25
83. Abdelmoneim SS, Bernier M, Dhoble A, Moir S, Hagen ME, Ness SAC, et al. Assessment ofmyocardial perfusion during adenosine stress using real time three-dimensional and twodimensional myocardial contrast echocardiography: comparison with single-photon emission computed tomography. Echocardiography. 2010;27:421-9
84. Tweet MS, Hayes SN, Pitta SR, Simari RD, Lerman A, Lennon RJ, et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126:579
85. Yip A, Saw J. Spontaneous coronary artery dissection-a review. Cardiovasc Diagn Ther. 2015;5:37-48
86. Mieres JH, Gulati M, Bairey Merz N, Berman DS, Gerber TC, Hayes SN, et al. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the american heart association. Circulation. 2014;130:350-79
87. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, et al. Exercise capacity and the risk of death in women: the st james women take heart project. Circulation. 2003;108:1554-9
88. Bourque JM, Holland BH, Watson DD, Beller GA. Achieving an exercise workload of≥ 10 metabolic equivalents predicts a very low risk of inducible ischemia: does myocardial perfusion imaging have a role? J Am Coll Cardiol. 2009;54:538-45
89. Kohli P, Gulati M. Exercise stress testing in women: going back to the basics. Circulation. 2010;122:2570-80
90. Hlatky MA, Pryor DB, Harrell Jr. FE, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography.Multivariable analysis. Am JMed. 1984;77:64-71
91. Alexander KP, Shaw LJ, Shaw LK, Delong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. J Am Coll Cardiol. 1998;32:1657-64
92. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical-diagnosis of coronary-artery disease. N Engl J Med. 1979;300:1350-8
93. Marwick TH, Nemec JJ, Pashkow FJ, Stewart WJ, Salcedo EE. Accuracy and limitations of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol. 1992;19:74-81
94. Williams MJ, Marwick TH, O’Gorman D, Foale RA. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women. Am J Cardiol. 1994;74:435-8
95. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: a meta-analysis. Am Heart J. 2001;142:934-44
96. Roger VL, Pellikka PA, Bell MR, Chow CW, Bailey KR, Seward JB. Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. Circulation. 1997;95:405-10
97. Arruda-Olson AM, Juracan EM, Mahoney DW, McCully RB, Roger VL, Pellikka PA. Prognostic value of exercise echocardiography in 5,798 patients: Is there a gender difference? J Am Coll Cardiol. 2002;39:625-31
98. McCully RB, Roger VL, Mahoney DW, Karon BL, Oh JK, Miller Jr. FA, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol. 1998;31:144-9
99. Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging. 2010;3:528-35
100. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age-and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results fromthe international multicenter confirm (coronary ct angiography evaluation for clinical outcomes: an international multicenter registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol. 2011;58:849-60
101. Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: The romicat (rule out myocardial infarction using computer assisted tomography) trial. J Am Coll Cardiol. 2009;53:1642-50
102. Schlett CL, Banerji D, Siegel E, Bamberg F, Lehman SJ, Ferencik M, et al. Prognostic value of ct angiography for major adverse cardiac events in patients with acute chest pain from the emergency department: 2-year outcomes of the romicat trial. JACC Cardiovasc Imaging. 2011;4:481-91
103. Devries S, Wolfkiel C, Fusman B, Bakdash H, Ahmed A, Levy P, et al. Influence of age and gender on the presence of coronary calcium detected by ultrafast computed tomography. J Am Coll Cardiol. 1995;25:76-82
104. Budoff MJ, Shokooh S, Shavelle RM, Kim HT, French WJ. Electron beam tomography and angiography: sex differences. Am Heart J. 2002;143:877-82
105. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015;372(14):1291-300
106. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: frommystery to reality. Eur Heart J. 2012;33:2771-2782b
107. Wei J, Mehta PK, Johnson BD, Samuels B, Kar S, Anderson RD, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease. JACC Cardiovasc Interv. 2012;5:646-53
108. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the national heart, lung and blood institute wise (women’s ischemia syndrome evaluation) study. J Am Coll Cardiol. 2010;55:2825-32
109. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008;51:997-1002
110. Bonetti PO, Pumper GM, Higano ST, Holmes Jr. DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137-41
111. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010;55: 1688-96
112. Sedlak TL, Lee M, Izadnegahdar M, Merz CNB, Gao M, Humphries KH. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J. 2013;166:38-44
113. Lerman A, Sopko G. Women and cardiovascular heart disease: clinical implications from the women’s ischemia syndrome evaluation (wise) study. Are we smarter? J Am Coll Cardiol. 2006;47: S59-62
114. Hasdai D, Cannan CR, Mathew V, Holmes Jr. DR, Lerman A. Evaluation of patients with minimally obstructive coronary artery disease and angina. Int J Cardiol. 1996;53:203-8
115. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr. DE, Ganiats TG, Holmes Jr. DR, et al. 2014 aha/acc guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139-228
116. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-st-segment elevation acute coronary syndromes: large-scale observations from the crusade (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the american college of cardiology/ american heart association guidelines) national quality improvement initiative. J Am Coll Cardiol. 2005;45:832-7
117. Gehrie ER, Reynolds HR, Chen AY, Neelon BH, Roe MT, Gibler WB, et al. Characterization and outcomes of women and men with non-st-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the acc/aha guidelines (crusade) quality improvement initiative. Am Heart J. 2009;158: 688-94
118. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. Gender differences in the management and clinical outcome of stable angina. Circulation. 2006;113:490-8
119. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the global registry of acute coronary events. Heart. 2009;95:20-6
120. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective clarify registry. Eur Heart J. 2012;33:2831-40
121. Collaborative overview of randomised trials of antiplatelet therapy- i: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ. 1994;308:81-106
122. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562-72
123. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420-7
124. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk. 1996;3:209-12
125. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med. 2008;359:2195-207
126. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22
127. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (care) trial. J Am Coll Cardiol. 1998;32:140-6
128. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350: 1495-504
129. O’Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-stsegment elevation myocardial infarction: a meta-analysis. JAMA. 2008;300:71-80
130. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in women. Am J Cardiol. 1995;75:340-3
131. Balady GJ, Ades PA, Bittner VA, Franklin BA, Gordon NF, Thomas RJ, et al. Referral, enrollment, and delivery of cardiac rehabilitation/ secondary prevention programs at clinical centers and beyond a presidential advisory from the american heart association. Circulation. 2011;124:2951-60
132. Lerman A, Burnett Jr. JC, Higano ST, McKinley LJ, Holmes Jr. DR. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97: 2123-8
133. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35:1101-11
134. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321-33
135. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291:1701-12
136. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249-60
137. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409
138. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease - the women’s health initiative. Arch Intern Med. 2006;166:357-65
139. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (hers) research group. JAMA. 1998;280:605-13
140. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57